Phase I Testing Sample Clauses

Phase I Testing. Assuming that the final bypass construction is completed by the 2003 juvenile migration, the District will use the first year of the operation (2003) of the juvenile bypass system to identify operational and maintenance modifications that may be needed. The District will conduct a pilot study, estimating the parameters that will be used in future survival studies. The District will begin testing the applicable survival standard in 2004. Beginning in 2004, the District proposes to use acoustic tag technology to measure Juvenile Dam Passage Survival or Juvenile Project Survival. Current coordination between the District, consultants, NMFS Science Center, and the USGS Biological Research Division is ongoing to design and develop the acoustic tag survival methodology. The results of this effort will then be presented to the Coordinating Committee before study implementation for approval. Between 2004 and 2006, chinook yearlings will be tested. Steelhead tests will begin between 2004 and 2006 as determined by the Coordinating Committee. Sockeye and sub-yearling chinook will be tested if technology exists, or will be calculated as discussed above if not measured by the end of Phase I testing.
Sample 1Sample 2Sample 3
AutoNDA by SimpleDocs
Phase I Testing. Beginning in 2002, the District proposes to use acoustic tag technology to measure Juvenile Dam Passage Survival or Juvenile Project Survival and PIT tags to measure Juvenile Project Survival. Current coordination between the District, consultants, NMFS Science Center, and the USGS Biological Research Division is ongoing to design and develop the acoustic tag survival methodology. The results of this effort will then be presented to the Coordinating Committee before study implementation for approval. Between 2002 and 2004, chinook yearlings will be tested. Steelhead tests will begin between 2002 and 2004 as determined by the Coordinating Committee. Sockeye and sub-yearling chinook will be tested if technology exists, or will be calculated as discussed above if not measured by the end of Phase I testing.
Sample 1
Phase I Testing. The goal of this task is to execute Phase I Testing and write a Test Report. • Execute testing according to the Phase I and Phase II Test Plan • Adjust test plan and re-test according to observed results • Collect at least 4 months of operations data from the ESS Module. The data collection period may be changed with prior CAM written approval. • Prepare a Phase I ESS Module Test Report that will include but is not limited to: o Summary of test plan, and any modifications made to plan o Summary of ESS and EVFC operations tested o Results of Testing • Phase I ESS Module Test Report
Sample 1
Phase I Testing. (a) Phase I Testing Minimum for Gene Groups 1 through 6. Monsanto shall, by the end of the Phase I Testing Period for each Gene Group: (i) conduct Phase I Testing, [* * *], on Collaboration Hit Homologs of at least [* * *] percent ([* * *]%) of the Collaboration Hits within such Gene Group, [* * *] (ii) conduct Phase I Testing [* * *] of at least [* * *] percent ([* * *]%) of the Collaboration Hits within such Gene Group, subject to a limit of [* * *] ([* * *]) Collaboration Hit Homologs in such Gene Group; and (iii) for the first [* * *] Collaboration Hit Homologs for which Evogene performed a Project G2P Round and delivered Preferred Modes of Use during Collaboration Year 5, conduct Phase I Testing (deemed to be within Gene Group 6) as set forth in Exhibit L, [* * *], of Preferred Modes of Use that are delivered by Evogene (within Collaboration Hits G2P Data Backpacks) for at least [* * *] ([* * *]) Collaboration Hit Homologs and/or Special Collaboration Hits, it being understood that Phase I Testing of a Collaboration Hit Homolog in Corn also constitutes Phase I Testing of such Collaboration Hit Homolog in the Main Monsanto Crops. Notwithstanding anything in this Section 5.10.1 to the contrary, if any Collaboration Hit Homolog of a Collaboration Hit in a Gene Group is advanced to Phase II in at least one of the Main Monsanto Crops within the Phase I Testing Period for such Gene Group, Monsanto shall be deemed to have met the Phase I Testing Minimum for such Gene Group. (b) Phase I Testing Minimum for Delivery Group 7. Monsanto shall, by the end of the Phase I Testing Period for Delivery Group 7: (i) conduct Phase I Testing, [* * *], in at least [* * *] ([* * *]) Collaboration Hits and/or Preferred Modes of Use within Delivery Group 7, and (ii) conduct Phase I Testing [* * *] on at least [* * *] ([* * *]) Collaboration Hits and/or Preferred Modes of Use within Delivery Group 7. *** Confidential treatment has been requested for redacted portions of this exhibit. This copy omits the information subject to the confidentiality request. Omissions are designated as [***]. A complete version of this exhibit has been provided separately to the Securities and Exchange Commission.
Sample 1
Phase I Testing 
Sample 1Sample 2Sample 3

Related to Phase I Testing

  • Random Testing Notwithstanding any provisions of the Collective Agreement or any special agreements appended thereto, section 4.6 of the Canadian Model will not be applied by agreement. If applied to a worker dispatched by the Union, it will be applied or deemed to be applied unilaterally by the Employer. The Union retains the right to grieve the legality of any imposition of random testing in accordance with the Grievance Procedure set out in this Collective Agreement.

  • Laboratory Testing All laboratories selected by UPS Freight for analyzing Controlled Substances Testing will be HHS certified.

  • Drug Testing (A) The state and the PBA agree to drug testing of employees in accordance with section 112.0455, F.S., the Drug-Free Workplace Act. (B) All classes covered by this Agreement are designated special risk classes for drug testing purposes. Special risk means employees who are required as a condition of employment to be certified under Chapter 633 or Chapter 943, F.S. (C) An employee shall have the right to grieve any disciplinary action taken under section 112.0455, the Drug-Free Workplace Act, subject to the limitations on the grievability of disciplinary actions in Article 10. If an employee is not disciplined but is denied a demotion, reassignment, or promotion as a result of a positive confirmed drug test, the employee shall have the right to grieve such action in accordance with Article 6.

  • Meter Testing Company shall provide at least twenty-four (24) hours' notice to Seller prior to any test it may perform on the revenue meters or metering equipment. Seller shall have the right to have a representative present during each such test. Seller may request, and Company shall perform, if requested, tests in addition to the every fifth-year test and Seller shall pay the cost of such tests. Company may, in its sole discretion, perform tests in addition to the fifth year test and Company shall pay the cost of such tests. If any of the revenue meters or metering equipment is found to be inaccurate at any time, as determined by testing in accordance with this Section 10.2 (Meter Testing), Company shall promptly cause such equipment to be made accurate, and the period of inaccuracy, as well as an estimate for correct meter readings, shall be determined in accordance with Section 10.3 (Corrections).

  • ODUF Testing 6.6.1 Upon request from TWTC, AT&T shall send ODUF test files to TWTC. The Parties agree to review and discuss the ODUF file content and/or format. For testing of usage results, AT&T shall request that TWTC set up a production (live) file. The live test may consist of TWTC’s employees making test calls for the types of services TWTC requests on ODUF. These test calls are logged by TWTC, and the logs are provided to AT&T. These logs will be used to verify the files. Testing will be completed within thirty (30) days from the date on which the initial test file was sent.

  • Inspection/Testing In order to assess Supplier’s work quality and/or compliance with this Order, upon reasonable notice by Buyer: (a) all goods, materials and services related to the items purchased hereunder, including, raw materials, components, assemblies, work in process, tools and end products shall be subject to inspection and testing by Buyer, its customer, representative or regulatory authorities at all places, including sites where the goods are made or located or the services are performed, whether at Supplier’s premises or elsewhere; and (b) all of Supplier’s facilities, books and records relating to this Order shall be subject to inspection by Buyer or its designee. If specific Buyer and/or Buyer’s customer tests, inspection and/or witness points are included in this Order, the goods shall not be shipped without an inspector’s release or a written waiver of test/inspection/witness with respect to each such point; however, Buyer shall not be permitted to unreasonably delay shipment; and Supplier shall notify Buyer in writing at least twenty (20) days prior to each of Supplier’s scheduled final and, if applicable, intermediate test/inspection/witness points. Supplier agrees to cooperate with such/audit inspection including, completing and returning questionnaires and making available its knowledgeable representatives. Buyer’s failure to inspect or test goods, materials or services or Buyer’s failure to reject or detect defects by inspection or testing shall not relieve Supplier from its warranty obligations or any of its other obligations or responsibilities under this Order. Supplier agrees to provide small business as well as minority and/or women owned business utilization and demographic data upon request.

  • Substance Abuse Testing The Parties agree that it is in the best interest of all concerned to promote a safe working environment. The Union has no objection to pre-employment substance abuse testing when required by the Employer and further, the Union has no objection to voluntary substance abuse testing to qualify for employment on projects when required by a project owner. The cost and scheduling of such testing shall be paid for and arranged by the Employer. The Union agrees to reimburse the Employer for any failed pre-access Alcohol and Drug test costs.

  • Product Testing No later than [**] prior to a scheduled Delivery ARIAD US shall send to ARIAD SWISSCO the Delivery Documents for review. Following such review, unless within [**] of receipt of the Delivery Documents ARIAD SWISSCO gives written notice of rejection of the Product to be delivered, stating the reasons for such rejection, the Delivery shall proceed, and both Parties shall organize the same. Upon arrival at ARIAD SWISSCO nominated site it shall visually inspect the shipment of the Product to identify any damage to the external packaging. ARIAD SWISSCO may reject any shipment (or portion thereof) of the Product that is damaged by providing to ARIAD US reasonable evidence of damage within [**] after Delivery of such Product. If ARIAD SWISSCO does not so reject any shipment (or portion thereof) of the Product within [**] of Delivery of such Product, ARIAD SWISSCO shall be deemed to have accepted such shipment of the Product; provided, however, that in the case of the Product having any Latent Defect, ARIAD SWISSCO shall notify ARIAD US promptly once it becomes aware that a Product contains a Latent Defect and subsequently may reject such Product by giving written notice to ARIAD US of ARIAD SWISSCO’s rejection of such Product and shipping a representative sample of such Product or other evidence of Non-Conformance to ARIAD US within [**] after becoming aware of such Latent Defect, which notice shall include a description of the Latent Defect.

  • Stability Testing Patheon may be requested to conduct stability testing on the Products in accordance with the protocols set out in the Specifications for the separate fees and during the time periods set out in Schedule C to a Product Agreement. Patheon will not make any changes to these testing protocols without prior written approval from Client. If a confirmed stability test failure occurs, Patheon will notify Client within one Business Day, after which Patheon and Client will jointly determine the proceedings and methods to be undertaken to investigate the cause of the failure, including which party will bear the cost of the investigation. Patheon will not be liable for these costs unless it has failed to perform the Manufacturing Services in accordance with the Specifications, cGMPs, and Applicable Laws. Patheon will give Client ail stability test data and results at Client’s request.

  • Random Drug Testing All employees covered by this Agreement shall be subject to random drug testing in accordance with Appendix D.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!